CARL
Carlsmed·NASDAQ
--
--(--)
--
--(--)
CARL fundamentals
During Q4 2025, Carlsmed (CARL) reported revenue of 15.16M, a YoY change of 61.19%. Net income was -8.61M, a YoY change of -82.48%. Click to view the full income statement and explore the company's earnings performance.
Income Statement
Q1,2024 | Q2,2024 | Q3,2024 | Q4,2024 | Q1,2025 | Q2,2025 | Q3,2025 | Q4,2025 | TTM |
|---|
Start Date | Jan 1, 2024 | Apr 1, 2024 | Jul 1, 2024 | Oct 1, 2024 | Jan 1, 2025 | Apr 1, 2025 | Jul 1, 2025 | Oct 1, 2025 | -- |
End Date | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | -- |
Fiscal Year-End | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | -- |
Revenue | 5.09M -- | 6.08M -- | 6.59M -- | 9.41M -- | 10.19M +100.33% | 12.08M +98.70% | 13.07M +98.39% | 15.16M +61.19% | 50.51M -- |
Sales and Services Revenue | 5.09M -- | 6.08M -- | 6.59M -- | 9.41M -- | 10.19M +100.33% | 12.08M +98.70% | 13.07M +98.39% | 15.16M +61.19% | 50.51M -- |
Cost of Revenue | 1.42M -- | 1.52M -- | 1.79M -- | 2.38M -- | 2.55M +79.54% | 3.21M +111.59% | 3.15M +75.61% | 3.56M +49.20% | 12.47M -- |
Cost of Goods and Services | 1.42M -- | 1.52M -- | 1.79M -- | 2.38M -- | 2.55M +79.54% | 3.21M +111.59% | 3.15M +75.61% | 3.56M +49.20% | 12.47M -- |
Gross Profit | 3.66M -- | 4.56M -- | 4.80M -- | 7.02M -- | 7.64M +108.41% | 8.87M +94.41% | 9.93M +106.90% | 11.61M +65.26% | 38.04M -- |
Operating Expenses | 8.99M -- | 10.88M -- | 12.57M -- | 11.72M -- | 13.36M +48.50% | 15.37M +41.26% | 18.96M +50.79% | 20.93M +78.53% | 68.61M -- |
Selling, General and Administrative Expenses | 5.74M -- | 6.88M -- | 8.54M -- | 8.71M -- | 10.21M +77.88% | 11.21M +62.88% | 14.52M +69.99% | 15.66M +79.90% | 51.59M -- |
Selling and Marketing Expenses | 3.60M -- | 4.87M -- | 6.62M -- | 6.38M -- | 6.74M +87.35% | 7.87M +61.48% | 9.61M +45.12% | 10.81M +69.42% | 35.03M -- |
General and Administrative Expenses | 2.14M -- | 2.01M -- | 1.92M -- | 2.33M -- | 3.47M +61.96% | 3.34M +66.27% | 4.91M +155.84% | 4.85M +108.64% | 16.57M -- |
Research and Development Expenses | 3.26M -- | 4.00M -- | 4.04M -- | 3.02M -- | 3.15M -3.26% | 4.16M +4.05% | 4.45M +10.16% | 5.26M +74.59% | 17.02M -- |
Operating Income | -5.33M -- | -6.32M -- | -7.78M -- | -4.70M -- | -5.72M -7.32% | -6.50M -2.90% | -9.04M -16.18% | -9.32M -98.38% | -30.57M -- |
Non-Operating Income (Loss) | -118.00K -- | 42.00K -- | -36.00K -- | -23.00K -- | -10.00K +91.53% | -264.00K -728.57% | 509.00K +1513.89% | 705.00K +3165.22% | 940.00K -- |
Gain (Loss) on Change in Fair Value | 0 -- | -61.00K -- | -28.00K -- | -55.00K -- | -33.00K -- | -237.00K -288.52% | -65.00K -132.14% | 7.00K +112.73% | -328.00K -- |
Net Interest Expense | 118.00K -- | -103.00K -- | 8.00K -- | -32.00K -- | -23.00K -119.49% | 27.00K +126.21% | -574.00K -7275.00% | -698.00K -2081.25% | -1.27M -- |
Interest Expense | 216.00K -- | 325.00K -- | 402.00K -- | 378.00K -- | 357.00K +65.28% | 363.00K +11.69% | 380.00K -5.47% | 330.00K -12.70% | 1.43M -- |
Interest Income | 98.00K -- | 428.00K -- | 394.00K -- | 410.00K -- | 380.00K +287.76% | 336.00K -21.50% | 954.00K +142.13% | 1.03M +150.73% | 2.70M -- |
Pretax Income From Continuing Operations | -5.45M -- | -6.28M -- | -7.81M -- | -4.72M -- | -5.73M -5.18% | -6.77M -7.79% | -8.53M -9.13% | -8.61M -82.48% | -29.63M -- |
Net Income | -5.45M -- | -6.28M -- | -7.81M -- | -4.72M -- | -5.73M -5.18% | -6.77M -7.79% | -8.53M -9.13% | -8.61M -82.48% | -29.63M -- |
Net Income Attributable to Owners of the Company | -5.45M -- | -6.28M -- | -7.81M -- | -4.72M -- | -5.73M -5.18% | -6.77M -7.79% | -8.53M -9.13% | -8.61M -82.48% | -29.63M -- |
Preferred Stock Dividends | 0 -- | 0 -- | 592.00K -- | 0 -- | 584.00K -- | 0 -- | 0 -100.00% | 0 -- | 584.00K -- |
Net Income Attributable to Common Stockholders | -5.45M -- | -6.28M -- | -8.40M -- | -4.72M -- | -6.31M -15.90% | -6.77M -7.79% | -8.53M -1.44% | -8.61M -82.48% | -30.22M -- |
Total Comprehensive Income | -5.45M -- | -6.28M -- | -7.81M -- | -4.72M -- | -5.73M -5.18% | -6.77M -7.79% | -8.53M -9.13% | -8.61M -82.48% | -29.63M -- |
Total Comprehensive Income Attributable to Owners of the Company | -5.45M -- | -6.28M -- | -7.81M -- | -4.72M -- | -5.73M -5.18% | -6.77M -7.79% | -8.53M -9.13% | -8.61M -82.48% | -29.63M -- |
Basic EPS | -0.24 -- | -1.55 -- | -2.06 -- | -- -- | -0.26 -8.33% | -1.47 +5.16% | -0.4 +80.58% | -0.32 -- | -2.45 -- |
Basic EPS from Continuing Operations | -0.24 -- | -1.55 -- | -2.06 -- | -- -- | -0.26 -8.33% | -1.47 +5.16% | -0.4 +80.58% | -- -- | -- -- |
Diluted EPS | -0.24 -- | -1.55 -- | -2.06 -- | -- -- | -0.26 -8.33% | -1.47 +5.16% | -0.4 +80.58% | -- -- | -- -- |
Diluted EPS from Continuing Operations | -0.24 -- | -1.55 -- | -2.06 -- | -- -- | -0.26 -8.33% | -1.47 +5.16% | -0.4 +80.58% | -- -- | -- -- |
You can ask Aime
Did Carlsmed beat or miss consensus estimates last quarter?What is Carlsmed's gross profit margin?What factors drove the changes in Carlsmed's revenue and profit?What guidance did Carlsmed's management provide for the next earnings period?What is the market's earnings forecast for Carlsmed next quarter?What does Carlsmed do and what are its main business segments?What is the revenue and EPS growth rate for Carlsmed year over year?What were the key takeaways from Carlsmed’s earnings call?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
